Evidence map›Paper›PMID 31223207›Full record

ArticleBioinformation2018

Molecular docking analysis of Cianidanol fromGinkgo biloba with HER2+ breast cancer target.

Abiodun Julius Arannilewa, Oluwaseun Suleiman Alakanse, Adesola Oluwaseun Adesola, Oluwaseyi Israel Malachi, Ifedayo Michael Obaidu, Emmanuel Ekun Oluwafemi, Emmanuel Damilola Afolayan, Patricia Folakemi Afere, Kayode Abdullateef Ayuba, Tolulope Oluwafemi Bolarinwa and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioinformation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Abiodun Julius ArannilewaDepartment of Biochemistry, University of Ilorin, Ilorin, Nigeria.
Oluwaseun Suleiman AlakanseDepartment of Biochemistry, University of Ilorin, Ilorin, Nigeria.
Adesola Oluwaseun AdesolaDepartment of Biochemistry, Federal University of Technology, Akure, Nigeria.
Oluwaseyi Israel MalachiFood Production Department, Goodfoods Inc., Montreal, QC, Canada.
Ifedayo Michael ObaiduDepartment of Biochemistry, Ekiti State University, Ado Ekiti,Nigeria.
Emmanuel Ekun OluwafemiDepartment of Biochemistry, AdekunleAjasin University, Akungba Akoko, Nigeria.
Emmanuel Damilola AfolayanDepartment of Biochemistry, University of Ilorin, Ilorin, Nigeria.
Patricia Folakemi AfereDepartment of Biochemistry, University of Ilorin, Ilorin, Nigeria.
Kayode Abdullateef AyubaDepartment of Biochemistry, University of Ilorin, Ilorin, Nigeria.
Tolulope Oluwafemi BolarinwaDepartment of Biochemistry, Federal University of Technology, Akure, Nigeria.
George Oche AmbroseDepartment of Biochemistry, University of Ilorin, Ilorin, Nigeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HER2 is a known therapeutic target for about 30% of breast cancer patients where HER2 is over expressed and this is referred to as HER2 positive breast cancer. This subtype is characterized by a clinical behavior know to be especially aggressive. Improved HER2 targeting agents such as trastuzumab, pertuzumb, lapatinib and ado-trastuzumab emtansine are available. Some patients have shown no response to treatment while others show progress to these agents. Therefore, it is of interest to screen HER2+ with phyto-chemical lead compound from Ginkgo biloba using molecular docking techniques. We screened 25 phyto-chemicals from literature with HER2+. Results show that cianidanol have an acceptable binding energy of (-8.2kcal/mol). Thus, we report the binding properties of cianidanol with HER2+.

Indexed as

CianidanolGinkgo bilobaHER2

Identifiers

PMID31223207
PMCPMC6563659

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.